Market capitalization | $563.13m |
Enterprise Value | $390.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 133.57 |
P/S ratio (TTM) P/S ratio | 192.85 |
P/B ratio (TTM) P/B ratio | 7.13 |
Revenue growth (TTM) Revenue growth | 57.64% |
Revenue (TTM) Revenue | $2.92m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
10 Analysts have issued a IGM Biosciences Inc forecast:
10 Analysts have issued a IGM Biosciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.92 2.92 |
58%
58%
|
|
Gross Profit | -6.02 -6.02 |
41%
41%
|
|
EBITDA | -212 -212 |
13%
13%
|
EBIT (Operating Income) EBIT | -221 -221 |
13%
13%
|
Net Profit | -220 -220 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firms product pipe line includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies; IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies; and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Mary Harler |
Employees | 224 |
Founded | 2010 |
Website | www.igmbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.